
OIS Podcast | Ophthalmology's leading Podcast
OIS Podcast
Welcome to the Ophthalmology Innovation Podcast Where you get Candid Conversations with the Leaders and Drivers of Ophthalmic Innovation. OIS is the Largest and Original Producer of World-Class Ophthalmology Innovation Conferences and Content Since 2009.
All episodes
Best episodes
Seasons
Top 10 OIS Podcast | Ophthalmology's leading Podcast Episodes
Goodpods has curated a list of the 10 best OIS Podcast | Ophthalmology's leading Podcast episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to OIS Podcast | Ophthalmology's leading Podcast for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite OIS Podcast | Ophthalmology's leading Podcast episode by adding your comments to the episode page.

DigiSight Puts Eye Care in Patients’ Hands
OIS Podcast | Ophthalmology's leading Podcast
02/03/15 • 20 min
The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation.Learn more about:SponsorshipPresenting CompaniesAny other questions? Contact the producer of OIS, Craig Simak.

What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.
OIS Podcast | Ophthalmology's leading Podcast
03/21/19 • 22 min
We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.

Sun Ophthalmics Looks to Build a Brand-New Business in the US
OIS Podcast | Ophthalmology's leading Podcast
04/28/16 • 19 min

Avedro’s Long Wait for FDA Approval is Over
OIS Podcast | Ophthalmology's leading Podcast
04/20/16 • 12 min

Dr. Pravin Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments
OIS Podcast | Ophthalmology's leading Podcast
09/28/17 • 21 min

ClarVista’s Two-Part Strategy To Premium IOLs
OIS Podcast | Ophthalmology's leading Podcast
08/19/15 • 27 min

Digital Health Is Dead? Don’t Tell Mark Blumenkranz, the FDA, or the Organizers of an Oct. Workshop
OIS Podcast | Ophthalmology's leading Podcast
09/13/17 • 37 min

CEO Ram Rao Discusses Juvene, the Rise of Presbyopia, and How LensGen Raised $21 million
OIS Podcast | Ophthalmology's leading Podcast
05/10/17 • 11 min

OIS Co-Chair Bill Link Walks Us Through OIS@ASCRS May 4 Agenda and Introduces Flying L Partners
OIS Podcast | Ophthalmology's leading Podcast
04/05/17 • 21 min

Breaking Barriers in Sustained Drug Delivery: Michael O’Rourke on The Rob & Jai Show edition of the OIS Podcast
OIS Podcast | Ophthalmology's leading Podcast
03/14/25 • 13 min
In this episode of The Rob & Jai Show, Michael O’Rourke, CEO of Re-Vana Therapeutics, joins Dr. Rob Rothman and Dr. Jai Parekh to explore the next-generation of sustained drug delivery in ophthalmology. With millions of intravitreal injections administered annually for retinal diseases like AMD, the need for longer-lasting, more effective treatments has never been greater.
O’Rourke explains how Re-Vana’s proprietary hydrogel-based technologies are setting a new standard for biodegradable, sustained-release drug implants—offering six to twelve months of therapeutic coverage without the need for surgery. The discussion covers:
🔹How Re-Vana’s EyeLiefTM and OcuLiefTM technologies work to deliver biologics efficiently over extended periods.
🔹Why reducing injection frequency is critical for patient compliance, physician workflow, and overall treatment success.
🔹 The company’s clinical and investment strategy, including a $70M Series B raise to advance its lead asset, a six-month biodegradable fluocinolone acetonide implant.
🔹 The role of strategic partnerships in accelerating innovation, as major pharma companies seek delivery solutions for their retinal therapeutics.
🔹 The global impact of sustained-release biologics, and how Re-Vana is positioning itself as a leader in both the U.S. and European markets.
With a team of seasoned industry experts, strong investor backing, and an unwavering commitment to innovation, Re-Vana Therapeutics is redefining how we approach retinal disease treatment.
Don’t miss this insightful conversation—subscribe to the OIS podcast today and stay ahead of the curve in ophthalmic innovation!
Show more best episodes

Show more best episodes
FAQ
How many episodes does OIS Podcast | Ophthalmology's leading Podcast have?
OIS Podcast | Ophthalmology's leading Podcast currently has 420 episodes available.
What topics does OIS Podcast | Ophthalmology's leading Podcast cover?
The podcast is about Venture Capital, Entrepreneurship, Investing, Investment, Podcasts, Entrepreneurs, Business and Ophthalmology.
What is the most popular episode on OIS Podcast | Ophthalmology's leading Podcast?
The episode title 'Revolutionizing Eye Care' is the most popular.
What is the average episode length on OIS Podcast | Ophthalmology's leading Podcast?
The average episode length on OIS Podcast | Ophthalmology's leading Podcast is 28 minutes.
How often are episodes of OIS Podcast | Ophthalmology's leading Podcast released?
Episodes of OIS Podcast | Ophthalmology's leading Podcast are typically released every 7 days.
When was the first episode of OIS Podcast | Ophthalmology's leading Podcast?
The first episode of OIS Podcast | Ophthalmology's leading Podcast was released on Aug 4, 2014.
Show more FAQ

Show more FAQ